Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to 5.15%.

  • Ascendis Pharma A's EBIT Margin rose 1724300.0% to 5.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 47237.11%, marking a year-over-year increase of 473014800.0%. This contributed to the annual value of 68.7% for FY2024, which is 817900.0% up from last year.
  • Ascendis Pharma A's EBIT Margin amounted to 5.15% in Q3 2025, which was up 1724300.0% from 33.5% recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's EBIT Margin registered a high of 123555.16% during Q4 2024, and its lowest value of 16709.12% during Q1 2021.
  • Over the past 5 years, Ascendis Pharma A's median EBIT Margin value was 297.17% (recorded in 2023), while the average stood at 4157.48%.
  • In the last 5 years, Ascendis Pharma A's EBIT Margin plummeted by -134190000bps in 2021 and then soared by 1235672600bps in 2024.
  • Ascendis Pharma A's EBIT Margin (Quarter) stood at 130.71% in 2021, then plummeted by -393bps to 643.75% in 2022, then skyrocketed by 98bps to 12.09% in 2023, then surged by 1021723bps to 123555.16% in 2024, then crashed by -100bps to 5.15% in 2025.
  • Its last three reported values are 5.15% in Q3 2025, 33.5% for Q2 2025, and 103.23% during Q1 2025.